🇺🇸 ELRANATAMAB in United States

540 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Cytokine Release Syndrome — 157 reports (29.07%)
  2. Pyrexia — 57 reports (10.56%)
  3. Immune Effector Cell-Associated Neurotoxicity Syndrome — 56 reports (10.37%)
  4. Death — 49 reports (9.07%)
  5. Pneumonia — 49 reports (9.07%)
  6. Neutropenia — 39 reports (7.22%)
  7. Cytomegalovirus Infection — 37 reports (6.85%)
  8. Plasma Cell Myeloma — 34 reports (6.3%)
  9. Covid-19 — 32 reports (5.93%)
  10. Infection — 30 reports (5.56%)

Source database →

ELRANATAMAB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is ELRANATAMAB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for ELRANATAMAB in United States?

Marketing authorisation holder not available in our data.